CORAL SPRINGS, Fla.--(BUSINESS WIRE)--Nutra Pharma Corporation (OTCQB:NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have begun the process of registering their homeopathic treatment for chronic pain, Nyloxin™, in the country of South Africa. “According to ImpactRX, the South African market for analgesics is over $200M,” commented Rik J Deitsch, CEO of Nu
Reported by Business Wire 13 hours ago.
↧